Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a French biotechnology company developing innovative oncology drugs based on DNA-targeting and epigenetics, two of the most sought-after mechanisms of action in cancer treatment today.
The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
Onxeo’s R&D pipeline includes belinostat, an HDAC inhibitor (epigenetics) currently being developed in oral form to be used in combination with other anti-cancer agents for liquid or solid tumors. Belinostat is already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo’s partner, Spectrum Pharmaceuticals, under the name Beleodaq® (belinostat IV form).
Onxeo is also developing AsiDNA™, a first-in-class DNA break repair inhibitor based on a unique decoy mechanism. AsiDNA™ has already successfully completed a Phase I trial in metastatic melanoma via local administration, and is currently being developed for systemic (IV) administration in solid tumors.
AsiDNA™ is the first compound generated from platON™, the Company’s proprietary chemistry platform of decoy oligonucleotides based on three components, a sequence of double strand oligonucleotides, a linker and a cellular uptake facilitator. PlatON™ will continue to generate new compounds that will broaden Onxeo’s pipeline.
For further information, please visit www.onxeo.com.
Location: France, Ile-de-France, Paris
Member count: 51-200
Total raised: $38.745099M
Founded date: 2014
Investors 2
Date | Name | Website |
- | Auriga Par... | auriga.vc |
- | Idinvest P... | idinvest.c... |
Funding Rounds 3
Date | Series | Amount | Investors | Deal News |
- | - | $14.202318... | - | healthcap.... |
- | - | $17.042781... | - | healthcap.... |
- | - | $7.5M | - | healthcap.... |
Mentions in press and media 46
Date | Title | Description | Category | Author | Source |
23.11.2021 | Onxeo Cont... | Bryan Giraudo, COO & CFO o... | - | - | globenewsw... |
09.06.2021 | ONXEO Onx... | This new patent protects both ... | - | - | marketscre... |
31.05.2021 | ONXEO S.A.... | PARIS, May 31, 2021 (GLOBE NEW... | - | - | marketscre... |
21.05.2021 | ONXEO S.A.... | Regulatory News: Onxeo S.A. (... | - | - | marketscre... |
21.05.2021 | ONXEO S.A.... | Paris (France), May 21, 2021 -... | - | - | marketscre... |
24.09.2020 | ONXEO S.A.... | Public limited company with a ... | - | - | marketscre... |
09.06.2020 | ONXEO S.A.... | The funds raised will accelera... | - | - | marketscre... |
29.02.2016 | Onxeo anno... | The signal-interfering DNA (si... | - | - | medcitynew... |
- | Onxeo Comp... | Milestone completion in line w... | - | - | healthcap.... |
- | Combinatio... | Preclinical Research Published... | - | - | healthcap.... |
Show more